Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low.Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy.In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models.By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05).Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 2 vom: 10. Jan., Seite 2874-2889 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rico, María [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 05.03.2018 Date Revised 17.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.13760 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM266895131 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM266895131 | ||
| 003 | DE-627 | ||
| 005 | 20231224215519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.13760 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0889.xml |
| 035 | |a (DE-627)NLM266895131 | ||
| 035 | |a (NLM)27926515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rico, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2018 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low.Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy.In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models.By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05).Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a metronomics | |
| 650 | 4 | |a propranolol | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Propranolol |2 NLM | |
| 650 | 7 | |a 9Y8NXQ24VQ |2 NLM | |
| 700 | 1 | |a Baglioni, María |e verfasserin |4 aut | |
| 700 | 1 | |a Bondarenko, Maryna |e verfasserin |4 aut | |
| 700 | 1 | |a Laluce, Nahuel Cesatti |e verfasserin |4 aut | |
| 700 | 1 | |a Rozados, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a André, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Carré, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Scharovsky, O Graciela |e verfasserin |4 aut | |
| 700 | 1 | |a Menacho Márquez, Mauricio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 2 vom: 10. Jan., Seite 2874-2889 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:2 |g day:10 |g month:01 |g pages:2874-2889 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.13760 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 2 |b 10 |c 01 |h 2874-2889 | ||